Key result
No-reflow following primary percutaneous coronary intervention for ST elevation myocardial infarction was an independent predictor of 12-month mortality.
Why the study?
Does no-reflow post primary PCI for STEMI predict 12-month mortality?
Cohort (n=764)
No
Does no-reflow post primary PCI for STEMI predict 12-month mortality?
No-reflow after primary PCI for STEMI occurs in 25% of cases, is driven by older age, high thrombus burden, and delayed presentation, and independently predicts 12-month mortality.
Answers are grounded in this paper and cite their sources.
May identify higher 12-month mortality risk after STEMI PCI; leaves open whether no-reflow prevention improves survival.
BACKGROUND: No-reflow (TIMI < 3) during primary PCI (PCI) for STEMI occurs in 11-41% of cases, indicates poor myocardial tissue perfusion, and is associated with a poor outcome. We aimed to determine predictors and 12 month outcomes of patients who developed no-reflow. METHODS: We analysed the PCI database of The Canberra Hospital and identified 781 patients who underwent primary PCI during 2008-2012. Follow-up at 12 months was with letter, phone call and review of hospital records. RESULTS: No-reflow was observed in 189 patients (25%) at the end of the procedure. Patients with no-reflow were older (64 vs. 61 years, p = 0.03). No-reflow patients were more likely to have initial TIMI flow < 3 (89% vs. 79%, p = 0.001), thrombus score ≥ 4 (83% vs. 69%, p = 0.0001), higher use of glycoprotein IIb/IIIa inhibitors (57% vs. 48%, p = 0.03) and longer median symptom to balloon time (223 min vs. 192 min, p = 0.004). No-reflow was an independent predictor of mortality (HR 1.95, CI 1.04-3.59, p = 0.037) during 12 month follow-up. On multivariate analysis, age > 60 years, thrombus score ≥ 4 and symptom to balloon time > 360 min were independent predictors of no-reflow. In 17% of cases of no reflow, it occurred only after stent insertion. CONCLUSIONS: No-reflow occurred in 25% of STEMI patients undergoing primary PCI and was more likely with older age, high thrombus burden and delayed presentation. No-reflow was associated with a higher risk of death at 12 month follow-up.
No takes yet. Share an insight, caveat, or question.
Mazhar et al. (2015) conducted a cohort in ST elevation myocardial infarction (STEMI) (n=764). No-reflow (TIMI < 3) vs. Normal flow was evaluated on All-cause mortality at 12 months (HR 1.95, 95% CI 1.04-3.59, p=0.037). No-reflow following primary percutaneous coronary intervention for ST elevation myocardial infarction was an independent predictor of 12-month mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: